

# Gary M Clifford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1213435/publications.pdf>

Version: 2024-02-01

127  
papers

13,399  
citations

50276

46  
h-index

22832

112  
g-index

127  
all docs

127  
docs citations

127  
times ranked

11116  
citing authors

#	ARTICLE	IF	CITATIONS
1	Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies. <i>Journal of Infectious Diseases</i> , 2023, 227, 488-497.	4.0	10
2	Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study. <i>International Journal of Cancer</i> , 2022, 150, 290-302.	5.1	18
3	Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa. <i>International Journal of Cancer</i> , 2022, 150, 761-772.	5.1	19
4	Epstein-Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018. <i>International Journal of Cancer</i> , 2022, 150, 753-760.	5.1	4
5	Cervical cancer in women living in South Africa: a record linkage study of the National Health Laboratory Service and the National Cancer Registry. <i>Ecancermedicalscience</i> , 2022, 16, 1348.	1.1	5
6	Burden of Kaposi sarcoma according to HIV status: A systematic review and global analysis. <i>International Journal of Cancer</i> , 2022, 150, 1948-1957.	5.1	9
7	Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay. <i>Microbiology Spectrum</i> , 2022, 10, e0148021.	3.0	9
8	Sero-prevalence of 19 infectious pathogens and associated factors among middle-aged and elderly Chinese adults: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e058353.	1.9	5
9	Molecular Risk Stratification for Anal Cancer Prevention. <i>Clinical Infectious Diseases</i> , 2021, 72, 2164-2166.	5.8	3
10	A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. <i>International Journal of Cancer</i> , 2021, 148, 38-47.	5.1	214
11	Estimates of the global burden of cervical cancer associated with HIV. <i>The Lancet Global Health</i> , 2021, 9, e161-e169.	6.3	319
12	Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. <i>Preventive Medicine</i> , 2021, 144, 106293.	3.4	10
13	Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. <i>PLoS Genetics</i> , 2021, 17, e1009254.	3.5	19
14	Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. <i>Lancet Public Health</i> , The, 2021, 6, e510-e521.	10.0	39
15	For Anal Cancer, Not All Women Are Equal. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, 2140.	0.4	1
16	Prevalence and risk factors for anogenital HPV infection and neoplasia among women living with HIV in China. <i>Sexually Transmitted Infections</i> , 2021, , sextrans-2021-055019.	1.9	3
17	History of tonsillectomy and risk of oropharyngeal cancer. <i>Oral Oncology</i> , 2021, 117, 105302.	1.5	3
18	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. <i>Lancet HIV</i> , the, 2021, 8, e531-e543.	4.7	77

#	ARTICLE	IF	CITATIONS
19	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. <i>Viruses</i> , 2021, 13, 1948.	3.3	7
20	The relative and attributable risks of cardia and non-cardia gastric cancer associated with <i>Helicobacter pylori</i> infection in China: a case-cohort study. <i>Lancet Public Health</i> , The, 2021, 6, e888-e896.	10.0	78
21	Cervical cancer risk in women living with HIV across four continents: A multicohort study. <i>International Journal of Cancer</i> , 2020, 146, 601-609.	5.1	37
22	Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status. <i>International Journal of Cancer</i> , 2020, 146, 1514-1522.	5.1	23
23	<i>FAM19A4</i> /miR124 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. <i>International Journal of Cancer</i> , 2020, 147, 1215-1221.	5.1	40
24	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. <i>International Journal of Cancer</i> , 2020, 147, 757-765.	5.1	5
25	Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China. <i>Cancer Medicine</i> , 2020, 9, 374-384.	2.8	24
26	Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. <i>The Lancet Global Health</i> , 2020, 8, e180-e190.	6.3	1,092
27	Incidence and Clearance of Anal Human Papillomavirus (HPV)-16 and HPV-18 Infection, and Their Determinants, Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in France. <i>Journal of Infectious Diseases</i> , 2020, 221, 1488-1493.	4.0	15
28	Time trends and other sources of variation in <i>Helicobacter pylori</i> infection in mainland China: A systematic review and meta-analysis. <i>Helicobacter</i> , 2020, 25, e12729.	3.5	34
29	Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018. <i>Annals of Internal Medicine</i> , 2020, 173, 888-894.	3.9	14
30	Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention. <i>International Journal of Cancer</i> , 2020, 147, 2677-2686.	5.1	44
31	Detection of a large spectrum of viral infections in conjunctival premalignant and malignant lesions. <i>International Journal of Cancer</i> , 2020, 147, 2862-2870.	5.1	8
32	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. <i>Nature Communications</i> , 2020, 11, 886.	12.8	52
33	Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: A systematic review and meta-analysis. <i>American Journal of Transplantation</i> , 2020, 20, 3520-3528.	4.7	16
34	Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort. <i>Vaccine</i> , 2020, 38, 4001-4005.	3.8	27
35	The Utility of Digital Anal Rectal Examinations in a Public Health Screening Program for Anal Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 192-196.	1.9	25
36	Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan. <i>Emerging Infectious Diseases</i> , 2020, 27, 1-9.	4.3	21

#	ARTICLE	IF	CITATIONS
37	Hopes for Prevention of Anal Cancer in Women. <i>Journal of Infectious Diseases</i> , 2019, 221, 1210-1212.	4.0	0
38	Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 880-891.	9.1	85
39	Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. <i>Papillomavirus Research (Amsterdam, Neth)</i> 2018, 5, S2-S3. <a href="#">Tj ETQq1 1 0.784314.rgBT /Overlock 1011</a>	4.5	1
40	Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virus-infected Women: A Systematic Review and Meta-analysis of Treatment Failure. <i>Clinical Infectious Diseases</i> , 2019, 69, 1555-1565.	5.8	35
41	Prevalence of human herpesviruses infections in nonmalignant tonsils: The SPLIT study. <i>Journal of Medical Virology</i> , 2019, 91, 687-697.	5.0	15
42	Type-Specific Anal Human Papillomavirus Prevalence Among Men, According to Sexual Preference and HIV Status: A Systematic Literature Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2019, 219, 590-598.	4.0	67
43	Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus-Positive Men Who Have Sex with Men. <i>Journal of Infectious Diseases</i> , 2018, 217, 1535-1543.	4.0	33
44	A case-control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda. <i>International Journal of Cancer</i> , 2018, 143, 1348-1355.	5.1	30
45	Options for design of real-world impact studies of single-dose vaccine schedules. <i>Vaccine</i> , 2018, 36, 4816-4822.	3.8	11
46	Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 198-206.	9.1	294
47	Pooled analysis of HPV infection in paired anal and cervical samples, by HIV status. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, S2-S3.	4.5	1
48	Determinants of high-grade anal intraepithelial lesions in HIV-positive men having sex with men. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, S3.	4.5	0
49	Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. <i>PLoS Pathogens</i> , 2018, 14, e1007352.	4.7	77
50	Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM. <i>Aids</i> , 2018, 32, 2363-2371.	2.2	23
51	Evaluation of human-papillomavirus testing and visual inspection for cervical cancer screening in Rwanda. <i>BMC Women's Health</i> , 2018, 18, 59.	2.0	18
52	Prevalence and risk factors of human polyomavirus infections in non-malignant tonsils and gargles: the SPLIT study. <i>Journal of General Virology</i> , 2018, 99, 1686-1698.	2.9	10
53	CD4/CD8 ratio and lung cancer risk. <i>Lancet HIV</i> , the, 2017, 4, e103.	4.7	7
54	Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer. <i>Clinical Infectious Diseases</i> , 2017, 64, 1228-1235.	5.8	124

#	ARTICLE	IF	CITATIONS
55	Cervical cancer screening in rural Bhutan with the <i>care</i> HPV test on self-collected samples: an ongoing cross-sectional, population-based study (REACH-Bhutan). <i>BMJ Open</i> , 2017, 7, e016309.	1.9	15
56	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. <i>Cell</i> , 2017, 170, 1164-1174.e6.	28.9	221
57	Human papillomavirus antibody response following HAART initiation among MSM. <i>Aids</i> , 2017, 31, 561-569.	2.2	11
58	Cervical screening. <i>Aids</i> , 2017, 31, 1045-1046.	2.2	2
59	Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan. <i>Virology Journal</i> , 2017, 14, 74.	3.4	22
60	Evaluation of cytology versus human papillomavirus-based cervical cancer screening algorithms in Bhutan. <i>Oncotarget</i> , 2017, 8, 72438-72446.	1.8	8
61	Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study. <i>International Journal of Cancer</i> , 2016, 138, 1732-1740.	5.1	72
62	Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. <i>International Journal of Cancer</i> , 2016, 139, 518-526.	5.1	38
63	Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2031-2038.	3.9	31
64	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	5.8	20
65	Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme. <i>BMC Infectious Diseases</i> , 2016, 16, 225.	2.9	40
66	Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 332-339.	2.1	77
67	Analysis of human papillomavirus 16 variants and risk for cervical cancer in Chinese population. <i>Virology</i> , 2016, 488, 156-161.	2.4	46
68	Judging the carcinogenicity of rare human papillomavirus types. <i>International Journal of Cancer</i> , 2015, 136, 740-742.	5.1	17
69	Deep brush-based cytology in tonsils resected for benign diseases. <i>International Journal of Cancer</i> , 2015, 137, 2994-2999.	5.1	18
70	Human Papillomavirus Antibodies and Future Risk of Anogenital Cancer: A Nested Case-Control Study in the European Prospective Investigation Into Cancer and Nutrition Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 877-884.	1.6	53
71	Hepatitis C Virus Seroprevalence in Mongolian Women Assessed by a Novel Multiplex Antibody Detection Assay. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1360-1365.	2.5	14
72	Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide. <i>Journal of Virology</i> , 2015, 89, 10680-10687.	3.4	78

#	ARTICLE	IF	CITATIONS
73	Introduction of a National HPV vaccination program into Bhutan. <i>Vaccine</i> , 2015, 33, 3726-3730.	3.8	51
74	Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). <i>Cancer Epidemiology</i> , 2014, 38, 748-756.	1.9	37
75	Urine testing for HPV: rationale for using first void. <i>BMJ, The</i> , 2014, 349, g6252-g6252.	6.0	37
76	Cervical cancer screening program in Thimphu, Bhutan: population coverage and characteristics associated with screening attendance. <i>BMC Women's Health</i> , 2014, 14, 147.	2.0	8
77	Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. <i>Virology</i> , 2014, 448, 356-362.	2.4	29
78	Human Papillomavirus 45 Genetic Variation and Cervical Cancer Risk Worldwide. <i>Journal of Virology</i> , 2014, 88, 4514-4521.	3.4	30
79	Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. <i>BMC Infectious Diseases</i> , 2014, 14, 408.	2.9	22
80	Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. <i>International Journal of Cancer</i> , 2014, 135, 2453-2461.	5.1	51
81	Prevalence of HPV infection and other risk factors in a Fijian population. <i>Infectious Agents and Cancer</i> , 2014, 9, 14.	2.6	13
82	Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. <i>International Journal of Cancer</i> , 2013, 132, 63-71.	5.1	106
83	Human papillomavirus types in glandular lesions of the cervix: A meta-analysis of published studies. <i>International Journal of Cancer</i> , 2013, 132, 248-250.	5.1	25
84	Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study. <i>American Journal of Epidemiology</i> , 2013, 178, 877-884.	3.4	116
85	Clifford et al. Respond to "Biological and Clinical Insights From Epidemiologic Research Into HIV, HPV, and Anal Cancer". <i>American Journal of Epidemiology</i> , 2013, 178, 888-889.	3.4	3
86	Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. <i>Journal of Virology</i> , 2012, 86, 6855-6861.	3.4	136
87	Prevalence of Cervical Human Papillomavirus (HPV) Infection in Vanuatu. <i>Cancer Prevention Research</i> , 2012, 5, 746-753.	1.5	13
88	Dried Blood Spot Samples for Seroepidemiology of Infections with Human Papillomaviruses, <i>Helicobacter pylori</i> , Hepatitis C Virus, and JC Virus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 287-293.	2.5	32
89	Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. <i>International Journal of Cancer</i> , 2012, 131, 949-955.	5.1	62
90	Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. <i>International Journal of Cancer</i> , 2012, 131, E156-61.	5.1	61

#	ARTICLE	IF	CITATIONS
91	Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. <i>International Journal of Cancer</i> , 2012, 131, 2349-2359.	5.1	706
92	Human papillomavirus infection in women with and without cervical cancer in Tbilisi, Georgia. <i>Cancer Epidemiology</i> , 2011, 35, 465-470.	1.9	19
93	HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. <i>Blood</i> , 2011, 117, 6100-6108.	1.4	99
94	Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. <i>International Journal of Cancer</i> , 2011, 128, 927-935.	5.1	853
95	Human papillomavirus infection in a population-based sample of women in Algiers, Algeria. <i>International Journal of Cancer</i> , 2011, 128, 2224-2229.	5.1	29
96	Author's reply to: Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. <i>International Journal of Cancer</i> , 2011, 129, 1283-1285.	5.1	1
97	Judging the carcinogenicity of human papillomavirus types by single/multiple infection ratio in cervical cancer. <i>International Journal of Cancer</i> , 2011, 129, 1792-1794.	5.1	14
98	Risks for Persistence and Progression by Human Papillomavirus Type 16 Variant Lineages Among a Population-Based Sample of Danish Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1315-1321.	2.5	72
99	Genome-wide association study of HPV seropositivity. <i>Human Molecular Genetics</i> , 2011, 20, 4714-4723.	2.9	25
100	Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study. <i>Aids</i> , 2010, 24, 2245-2252.	2.2	20
101	Human papillomavirus infection in women with and without cervical cancer in Nepal. <i>Cancer Causes and Control</i> , 2010, 21, 323-330.	1.8	41
102	Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2379-2388.	2.5	46
103	Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. <i>Infectious Agents and Cancer</i> , 2010, 5, 24.	2.6	52
104	Cancer risk in HIV-infected persons: influence of CD4 count. <i>Future Oncology</i> , 2009, 5, 669-678.	2.4	47
105	Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. <i>International Journal of Cancer</i> , 2009, 124, 1626-1636.	5.1	811
106	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 1065-1074.	1.0	92
107	Hodgkin lymphoma in the Swiss HIV Cohort Study. <i>Blood</i> , 2009, 113, 5737-5742.	1.4	92
108	Members of the human papillomavirus type 18 family (alpha7 species) share a common association with adenocarcinoma of the cervix. <i>International Journal of Cancer</i> , 2008, 122, 1684-1685.	5.1	73

#	ARTICLE	IF	CITATIONS
109	Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials. <i>International Journal of Cancer</i> , 2008, 122, 719-720.	5.1	2
110	Human Papillomavirus Infection in Ulaanbaatar, Mongolia: A Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1731-1738.	2.5	67
111	Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. <i>Aids</i> , 2008, 22, 301-306.	2.2	124
112	Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. <i>Aids</i> , 2008, 22, 2135-2141.	2.2	145
113	Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1874-1879.	2.5	106
114	Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 453-459.	9.1	1,277
115	Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. <i>International Journal of Cancer</i> , 2007, 121, 621-632.	5.1	1,452
116	Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. <i>International Journal of Cancer</i> , 2007, 121, 1306-1311.	5.1	80
117	Human papillomavirus infection among 100 oesophageal cancer cases in the People's Republic of China. <i>International Journal of Cancer</i> , 2007, 121, 1396-1398.	5.1	11
118	Human papillomavirus types among women infected with HIV: a meta-analysis. <i>Aids</i> , 2006, 20, 2337-2344.	2.2	321
119	Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. <i>International Journal of Cancer</i> , 2006, 119, 2677-2684.	5.1	332
120	Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. <i>BJU International</i> , 2005, 95, 557-562.	2.5	56
121	HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2005, 115, 329-332.	5.1	59
122	No risk of drug-associated liver injury with $\alpha$ -adrenoreceptor blocking agents in men with BPH: results from an observational study using the GPRD. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 75-80.	1.9	4
123	Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests. <i>Journal of the National Cancer Institute</i> , 2005, 97, 938-939.	6.3	33
124	Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy. <i>Journal of the National Cancer Institute</i> , 2005, 97, 425-432.	6.3	814
125	Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1157-1164.	2.5	472
126	Human Papillomavirus Type 16 and TP53 Mutation in Oral Cancer. <i>Cancer Research</i> , 2004, 64, 468-471.	0.9	98



#	ARTICLE	IF	CITATIONS
127	Drug or symptom-induced depression in men treated with alpha1-blockers for benign prostatic hyperplasia? A nested case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 55-61.	1.9	22